Question to the Department of Health and Social Care:

To ask Her Majesty’s Government what action they have taken in the light of any representations they have received from Clinical Commissioning Groups about removing current barriers preventing them from using the drug bevacizumab in the treatment of age-related macular degeneration.

No action has been taken in response to the correspondence from clinical commissioning groups (CCGs) to remove current barriers to prevent them from using bevacizumab (Avastin) in the treatment of wet age-related macular degeneration (AMD). Bevacizumab is not licensed for use in the treatment of wet AMD. Unlicensed medicines can be used to treat patients where there is a special clinical need. There are two other effective licensed treatments for wet AMD recommended by the National Institute for Health and Care Excellence.